{
    "clinical_study": {
        "@rank": "129588", 
        "arm_group": [
            {
                "arm_group_label": "Percocet", 
                "arm_group_type": "Active Comparator", 
                "description": "Oxycodone/APAP (acetaminophen)"
            }, 
            {
                "arm_group_label": "Xartemis", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the analgesic efficacy of  Xartemis 15mg/650mg by\n      mouth every  12 hours for the management of acute moderate to severe post operative pain to\n      generic Oxycodone/APAP(acetaminophen) (Percocet) 10mg/650mg by mouth every 6 hours."
        }, 
        "brief_title": "An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Post Operative Pain", 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who provide written informed consent prior to enrollment\n\n          -  Male or female and 18 years of age or older.\n\n          -  Patients who are scheduled to undergo elective general surgery including, but not\n             limited to the following surgical types:\n\n               -  Abdominal surgery\n\n               -  Orthopedic surgery\n\n               -  Spine surgery\n\n               -  Genitourinary surgery\n\n          -  Patient classified as American Society of Anesthesiologists (ASA class I-III).\n\n          -  Female subjects are eligible only if all of the following apply:\n\n               -  Not pregnant (subjects of child bearing potential must have a negative beta\n                  human chorionic gonadotropin (\u03b2-hCG) pregnancy test before surgery);\n\n               -  Not lactating;\n\n               -  Not planning to become pregnant within the duration of the study;\n\n          -  Patients who are expected to have acute pain requiring oral opioid analgesics for at\n             least 48 hours during the post operative period (either inpatient or outpatient).\n\n          -  Patient must report a categorical pain rating of moderate to severe on a scale of\n             none, mild, moderate, or severe prior to randomization.\n\n          -  Patients who are willing and capable of understanding and cooperating with the\n             requirements of the study.\n\n          -  Patients able to understand and communicate in English.\n\n        Exclusion Criteria:\n\n          -  Patients with a medical condition that, in the Investigator's opinion, could\n             adversely impact the patient's participation, safety, or conduct of the study such as\n             but not limited to a history of severe renal or hepatic impairment, severe active\n             hepatic disease, or any other clinically significant medical condition that may\n             preclude safe study participation\n\n          -  Patients who have a known severe allergy or hypersensitivity to opioid analgesics,\n             anesthetics, APAP (acetaminophen.)\n\n          -  Patients who have a history of intolerance to short term opioid use.\n\n          -  Patients who have abused any prescription medication or alcohol within two years\n             before the start of the study.\n\n          -  Patients who require an additional scheduled surgical procedure within 48 hours of\n             the surgery.\n\n          -  Patients who have a history of seizures, or are currently taking anticonvulsants.\n\n          -  Patients who have dysphagia and/or cannot swallow study medication whole.\n\n          -  Patient who is unable to adequately communicate with study staff, properly give\n             informed consent, or otherwise comply with study procedures.\n\n          -  Patient who has participated in another clinical trial of an investigational drug or\n             device within 30 days of screening visit or is schedule to receive an investigational\n             product while participating in the study.\n\n        Post operative Exclusion Criteria at Randomization:\n\n          -  Patients who are not awake, not breathing spontaneously, or have a respiratory\n             insufficiency.\n\n          -  Patients who are vomiting and not responsive to standard treatment\n\n          -  Patients not able to answer questions and follow commands.\n\n          -  Patients who have surgical complications that could compromise safety of the subject\n             or confound the results of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101476", 
            "org_study_id": "LCR-MNK-01C"
        }, 
        "intervention": [
            {
                "arm_group_label": "Percocet", 
                "description": "10mg/650mg", 
                "intervention_name": "Percocet", 
                "intervention_type": "Drug", 
                "other_name": "Oxycodone/APAP(acetaminophen)"
            }, 
            {
                "arm_group_label": "Xartemis", 
                "description": "15mg/650mg", 
                "intervention_name": "Xartemis", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Acetaminophen, hydrocodone drug combination", 
                "Analgesics", 
                "Oxycodone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pain", 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "contact": {
                "email": "anne@lotuscr.com", 
                "last_name": "Anne Arriaga", 
                "phone": "626-397-3412"
            }, 
            "facility": {
                "address": {
                    "city": "Pasadena", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91105"
                }, 
                "name": "Lotus Clinical Resarch,LLC"
            }, 
            "investigator": {
                "last_name": "Neil Singla, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label,Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP (Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain", 
        "other_outcome": [
            {
                "description": "To assess healthcare professional global assessments at 48 hours and 120 hours after treatment initiation for Xartemis 15mg/650mg by mouth every 12 hours compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours.", 
                "measure": "Healthcare Professional Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "48 Hours"
            }, 
            {
                "description": "To assess healthcare professional global assessments at 48 hours and 120 hours after treatment initiation for Xartemis 15mg/650mg by mouth every 12 hours compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours.", 
                "measure": "Healthcare Professional Global Assessment", 
                "safety_issue": "No", 
                "time_frame": "120 Hours"
            }
        ], 
        "overall_official": {
            "affiliation": "Lotus Clinical Research, LLC", 
            "last_name": "Neil Singla, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To demonstrate the non inferiority of Xartemis 15mg/650mg by mouth every 12 hours for the management of acute post operative pain when compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours. The statistical comparison of interest will be the patient global assessment of analgesic effect administered at 48 hours after treatment initiation.", 
            "measure": "Non Inferiority", 
            "safety_issue": "No", 
            "time_frame": "48 Hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101476"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess patient global assessments at 120 hours after treatment initiation for Xartemis 15mg/650mg by mouth every 12 hours compared to generic Oxycodone/APAP (acetaminophen) 10mg/650mg by mouth every 6 hours.", 
            "measure": "Patient Global Assessment", 
            "safety_issue": "No", 
            "time_frame": "120 Hours"
        }, 
        "source": "Lotus Clinical Research, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Mallinckrodt Pharmaceuticals", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Lotus Clinical Research, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}